Hector Fernandez
-
mRNA-1273 Induced Robust Immune Responses in a Small Cohort of Older Adults
Summary: Results of a phase 1 trial have revealed that the Covid-19 vaccine developed by the US-based biotechnology company Moderna elicited a strong immune response in older adults with no serious adverse effects. Last week, Moderna released the results of the expansion of their phase 1 trial of mRNA-1273, one of the more prominent COVID…
-
US Government Announces SARS-CoV-2 Vaccine Distribution Strategy
Last week, the Trump administration released guidelines regarding the distribution strategy for a COVID-19 vaccine through the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD). These guidelines, found in this link, detail the American government’s plan to safely and effectively distribute a vaccine ahead of time as many of…
-
Findings from NVX-CoV237 Phase I/II Trial
Recently, findings of the phase I part of a phase I–II trial of Novavax’s vaccine candidate, which began in May 2020, were released in the New England Journal of Medicine. The vaccine candidate, called NVX-CoV2373, is a recombinant SARS-CoV-2 nanoparticle vaccine created from the full-length, wild-type, virus spike (S) glycoprotein which mediates viral entry in…